Cytotoxic Granule Protein Expression in ALCL, HD, and LBCL
| Cases . | TIA-1 . | Perforin . | Overall Positivity (%) . |
|---|---|---|---|
| . | (%) . | (%) . | . |
| ALCL | 23/33 (70) | 22/33 (67) | 25/33 (76) |
| Classical systemic | 13/19 (68) | 14/19 (74) | 15/19 (79) |
| Histiocyte rich variant | 6/6 (100) | 6/6 (100) | 6/6 (100) |
| Small cell variant | 2/2 (100) | 2/2 (100) | 2/2 (100) |
| Primary cutaneous | 0/3 | 0/3 | 0/3 |
| AIDS-associated | 2/3 (67) | 0/3 | 2/3 (67) |
| HD | 5/51 (10) | 0/26 | 5/51 (10) |
| LP HD | 0/3 | 0/1 | 0/3 |
| NS HD | 2/33 (6) | 0/18 | 2/33 (6) |
| MC HD | 2/11 (18) | 0/5 | 2/11 (18) |
| LD HD | 1/4 (25) | 0/2 | 1/4 (25) |
| LBCL | 0/17 (0) | 0/12 (0) | 0/17 (0) |
| Diffuse LBCL | 0/10 | 0/8 | 0/10 |
| T-cell rich BCL | 0/3 | 0/1 | 0/3 |
| Mediastinal LBCL | 0/2 | 0/1 | 0/2 |
| Follicular LBCL | 0/1 | 0/1 | 0/1 |
| LBCL with LP HD | 0/1 | 0/1 | 0/1 |
| Cases . | TIA-1 . | Perforin . | Overall Positivity (%) . |
|---|---|---|---|
| . | (%) . | (%) . | . |
| ALCL | 23/33 (70) | 22/33 (67) | 25/33 (76) |
| Classical systemic | 13/19 (68) | 14/19 (74) | 15/19 (79) |
| Histiocyte rich variant | 6/6 (100) | 6/6 (100) | 6/6 (100) |
| Small cell variant | 2/2 (100) | 2/2 (100) | 2/2 (100) |
| Primary cutaneous | 0/3 | 0/3 | 0/3 |
| AIDS-associated | 2/3 (67) | 0/3 | 2/3 (67) |
| HD | 5/51 (10) | 0/26 | 5/51 (10) |
| LP HD | 0/3 | 0/1 | 0/3 |
| NS HD | 2/33 (6) | 0/18 | 2/33 (6) |
| MC HD | 2/11 (18) | 0/5 | 2/11 (18) |
| LD HD | 1/4 (25) | 0/2 | 1/4 (25) |
| LBCL | 0/17 (0) | 0/12 (0) | 0/17 (0) |
| Diffuse LBCL | 0/10 | 0/8 | 0/10 |
| T-cell rich BCL | 0/3 | 0/1 | 0/3 |
| Mediastinal LBCL | 0/2 | 0/1 | 0/2 |
| Follicular LBCL | 0/1 | 0/1 | 0/1 |
| LBCL with LP HD | 0/1 | 0/1 | 0/1 |
Abbreviations: LD, lymphocyte depletion; LP, nodular lymphocyte predominance; MC, mixed cellularity; NS; nodular sclerosis.